GlassScriptPhysician profile
Gregory K Harter
NPI 1134157415
$14,109.21
in general payments reported to CMS, 2019-2025
41 companies · $2,132 in 2025
The $2,132 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $1,756 · 2021: $2,540 · 2022: $2,029 · 2023: $1,873 · 2024: $2,320 · 2025: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,324.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,945.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,696.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,267.42 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $1,156.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,046.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $682.82 | 2019-2025 | |
| Novo Nordisk INC | $465.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $461.79 | 2019-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $448.33 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $362.43 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Amgen INC. | $352.55 | 2020-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $316.89 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $312.13 | 2019-2022 | |
| Astellas Pharma US INC | $304.68 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $298.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Harter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.